EverCommerce's expected 107% annual growth rate to reach breakeven is seen as overly optimistic. The company's high debt level adds risk to investing in this loss-making firm.
EverCommerce is undervalued, presenting a potential opportunity for investors. The positive outlook and expected higher cash flow are not fully reflected in the share price. Financial health should also be considered.
EverCommerce's debt usage is worrisome due to its EBIT loss and liabilities surpassing its cash and near-term receivables. The company's balance sheet is deemed unfit, making the stock risky. However, future profitability will determine if it can bolster its balance sheet.
EverCommerce is believed to be undervalued given its intrinsic value and bullish future expectations. Investors are advised to consider both the company's strong future outlook and other factors like financial health before making investment decisions.
エバーコマースに関するコメント
• $モルフォシス (MOR.US)$ +7.9% (entered into equity participation and license agreements for felzartamab and MOR210)
• $デイ・ワン・バイオファーマシューティカルズ (DAWN.US)$ +7.4% (prices offering of 10 mln shares of common stock at $15.00 per share)
• $ハーツ・グローバル・ホールディングス (HTZ.US)$ +6.1% (authorizes new $2.0 bln share repurchase program)
• $エバーコマース (EVCM.US)$ +3.6% (announces $50 million share repurchase program)
• $スプリンクラー (CXM.US)$ +3.6% (In ...
まだコメントはありません